The Institute of Immunology of the Federal Medical and Biological Agency has submitted to the Ministry of Health of the Russian Federation documents for registration of a drug for the treatment of coronavirus Mir-19 (the name stands for small interfering RNA). According to TASS, the application was registered the day before, on October 14.
The drug is intended for the prevention and treatment of infection through inhalation or intranasal administration.
“Mir-19” stops the replication of the virus and prevents the most severe forms of the disease, as well as pneumonia.
The drug showed maximum effectiveness in the first two to three days after human infection.
The FMBA Institute received a patent for this drug in the spring of this year.